Revelation Biosciences posts Q2 2026 loss, holds $11.5M cash runway through Q1 2027, and advances pivotal AKI trial
REVB sits 28% above its 52-week low of $0.875 on light trading volume (0.1× avg).
Summary
Revelation Biosciences reported Q2 2026 financials with $11.5M in cash, funding operations only through Q1 2027, while advancing a pivotal AKI trial for Gemini. The company faces a tight cash runway and Nasdaq delisting risk, making the upcoming trial enrollment a critical milestone.
Key Events · Earnings and Guidance · REVB
-
Q2 2026 Net Loss of $3.3M
Net loss was $3.3 million ($0.87/share) for Q2 2026, compared to $2.4 million ($28.04/share) in Q2 2025. H1 2026 net loss was $6.3 million ($3.41/share).
-
Cash Runway Through Q1 2027
Cash and cash equivalents stood at $11.5 million as of June 30, 2026, which management believes is sufficient to fund operations only through the first quarter of 2027.
-
Pivotal AKI Trial Enrollment Targeted by Year-End
Start-up activities for the Phase 2/3 clinical study of Gemini in acute kidney injury are progressing, with enrollment expected to begin by the end of 2026.
-
$94B Addressable Market for Gemini
An independent market assessment estimated a potential $94 billion total addressable market for Gemini, highlighting the commercial opportunity if clinical development succeeds.
Analysis · REVB · Life Sciences
Revelation Biosciences disclosed Q2 2026 results with a net loss of $3.3 million and cash of $11.5 million, enough to fund operations only through the first quarter of 2027. The company is advancing a pivotal Phase 2/3 trial for Gemini in acute kidney injury, targeting enrollment by year-end, but the tight cash runway and ongoing Nasdaq delisting risk create significant uncertainty. The $94 billion addressable market estimate for Gemini underscores the potential upside if the trial succeeds, but the near-term survival question dominates.
At the time of this filing, REVB was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $0.88 to $11.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.